Advertisement

Topics

ERSPC (European Randomized Study of Screening for Prostate Cancer) Company Profile

12:04 EDT 25th June 2018 | BioPortfolio


News Articles [6500 Associated News Articles listed on BioPortfolio]

Researchers to investigate screening for prostate cancer using MRI

A new clinical study will test for the first time if MRI scans can be used for population screening to detect prostate cancer more accurately... The post

Single PSA screening increases prostate cancer detection but does not change mortality

1. In this randomized controlled trial, men who were screened with a single PSA test had higher diagnoses of prostate cancer than those who were unscreened. 2. There was no difference in mortality bet...

Fasting blood glucose, glycaemic control and prostate cancer risk in the Finnish Randomized Study of Screening for Prostate Cancer

Prostate cancer screening: massive study gets minimal coverage. Why?

The largest-ever randomized trial of using the prostate-specific antigen (PSA) test in asymptomatic men over the age of 50 has found — after about 10 years of follow-up — no significant di...

New Analysis Confirms Suspected Bias of Large U.S. Prostate Screening Study

A new paper appearing in Annals of Internal Medicine used simulation modeling to try to correct for a known bias in a notable U.S. trial of prostate cancer screening, called PLCO. That study along wi...

PSA screening for prostate cancer is not effective, report researchers

According to a new study, the one-off PSA screening test for prostate cancer does not save lives of asymptomatic men.

PSA Screening for Prostate Cancer

PSA testing is controversial. A new study finds that PSA screening for prostate cancer offers no survival benefits.

USPSTF recommendation statement on screening for prostate cancer

(JAMA Network) The US Preventive Services Task Force (USPSTF) recommends that men 55 to 69 who are interested in screening talk to their doctors about potential benefits and harms of screening for pro...

Drugs and Medications [843 Associated Drugs and Medications listed on BioPortfolio]

Avodart [GlaxoSmithKline LLC]

These highlights do not include all the information needed to use AVODART safely and effectively. See full prescribing information for AVODART. AVODART (dutasteride) Soft Gelatin CapsulesInitial U.S....

Avodart [Preferred Pharmaceuticals, Inc]

These highlights do not include all the information needed to use AVODART safely and effectively. See full prescribing information for AVODART. AVODART (dutasteride) Soft Gelatin CapsulesInitial U.S....

Avodart [Physicians Total Care, Inc.]

These highlights do not include all the information needed to use AVODART safely and effectively. See full prescribing information for AVODART. AVODART (dutasteride) Soft Gelatin CapsulesInitial U.S....

Fareston [GTx, Inc.]

These highlights do not include all the information needed to use FARESTON® safely and effectively. See full prescribing information for FARESTON®.FARESTON® (toremifene citrate) 60 mg Tablets oral ...

Jalyn [GlaxoSmithKline LLC]

These highlights do not include all the information needed to use JALYN safely and effectively. See full prescribing information for JALYN.JALYN (dutasteride and tamsulosin hydrochloride) CapsulesInit...

PubMed Articles [15084 Associated PubMed Articles listed on BioPortfolio]

The efficacy of prostate-specific antigen screening: Impact of key components in the ERSPC and PLCO trials.

The European Randomized Study of Screening for Prostate Cancer (ERSPC) demonstrated that prostate-specific antigen (PSA) screening significantly reduced prostate cancer mortality (rate ratio, 0.79; 95...

Costs of screening for prostate cancer: Evidence from the Finnish Randomised Study of Screening for Prostate Cancer after 20-year follow-up using register data.

Few empirical analyses of the impact of organised prostate cancer (PCa) screening on healthcare costs exist, despite cost-related information often being considered as a prerequisite to informed scree...

Men's perspectives of prostate cancer screening: A systematic review of qualitative studies.

Prostate cancer is the most commonly diagnosed non-skin cancer in men. Screening for prostate cancer is widely accepted; however concerns regarding the harms outweighing the benefits of screening exis...

Estimating the sensitivity of a prostate cancer screening programme for different PSA cut-off levels: A UK case study.

Policy decisions about prostate cancer screening require data on the natural history of histological cancers and the resulting impact of screening. However, the gold standard procedure required to ide...

Reconciling the Effects of Screening on Prostate Cancer Mortality in the ERSPC and PLCO Trials.

Clinical Trials [16190 Associated Clinical Trials listed on BioPortfolio]

A Randomized Trial of Early Detection of Clinically Significant Prostate Cancer (ProScreen)

A population-based randomised trial of prostate cancer screening will be carried out. A total of approximately 67,000 men aged 50-63 in Helsinki and Tampere are randomised to intervention ...

Facilitating Shared Decisionmaking About Prostate Cancer Screening

Due to the disputed efficacy of prostate cancer (CaP) screening and treatment, most authorities recommend that providers inform and involve patients in CaP screening decisions.

Screening for Cancer of the Prostate, Lung, Colon, Rectum, or Ovaries in Older Patients

RATIONALE: Screening for cancer may enable doctors to discover and treat the disease earlier. PURPOSE: Randomized trial to determine if screening methods used to diagnose cancer of the ...

Using Decision Analysis to Enhance Decision-Making Regarding Prostate Cancer Screening

The purpose of this study is to evaluate a new counseling tool for patients deciding whether or not to undergo prostate cancer screening. This screening decision aid is a computer program ...

Addressing Prostate Cancer Information Disparities With eHealth Technology

his is a multicenter study that involves research on screening for prostate cancer. This study pilot tests a culturally appropriate decision aid (DA) for African American (AA) men that wil...

Companies [2982 Associated Companies listed on BioPortfolio]

ERSPC (European Randomized Study of Screening for Prostate Cancer)

European Randomized Study of Screening for Prostate Cancer (ERSPC)

Prostate Cancer Education Council

Prostate cancer remains the second-leading cause of cancer death in American men. More than 220,000 men will be diagnosed with prostate cancer this year and it is expected that 27,000 men will die fro...

Prostate Cancer Foundation

The Prostate Cancer Foundation (PCF) is the world’s largest philanthropic source of support for accelerating the world’s most promising research for discovering better t...

The Prostate Cancer Foundation

The Prostate Cancer Foundation is the world’s largest philanthropic source of support for prostate cancer research focused on discovering better treatments and a cure for pro...

More Information about "ERSPC (European Randomized Study of Screening for Prostate Cancer)" on BioPortfolio

We have published hundreds of ERSPC (European Randomized Study of Screening for Prostate Cancer) news stories on BioPortfolio along with dozens of ERSPC (European Randomized Study of Screening for Prostate Cancer) Clinical Trials and PubMed Articles about ERSPC (European Randomized Study of Screening for Prostate Cancer) for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of ERSPC (European Randomized Study of Screening for Prostate Cancer) Companies in our database. You can also find out about relevant ERSPC (European Randomized Study of Screening for Prostate Cancer) Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Corporate Database Quicklinks



Searches Linking to this Company Record